Abstract
The aim of the study was to examine the in-vitro efficacy of the novel quinolone sitafloxacin (STFX) against periodontal disease-associated bacteria, and to compare its efficacy with other earlier-generation quinolones and antibiotics generally used in the treatment of periodontitis. Assessment of the antimicrobial susceptibilities [minimal inhibitory concentrations (MIC) based on agar dilution] revealed that sitafloxacin was the most effective (MIC≤0.25μg/ml) among the 6 antibiotics examined against all of the laboratory and clinical strains studied. Specifically, sitafloxacin showed higher antibacterial activity (MIC≤0.06μg/ml) than levofloxacin against not only Aggregatibacter actinomycetemcomitans, but also against other gram-negative anaerobic rods, including Porphyromonas gingivalis, Fusobacterium nucleatum, Prevotella intermedia, Prevotella nigrescens and Tannerella forsythia, on which the earlier-generation quinolones had limited effect.
These results suggest that sitafloxacin is an effective agent against major periodontal disease-associated bacteria.
Nihon Shishubyo Gakkai Kaishi(J Jpn Soc Periodontol)52(3) : 239-244, 2010.
